BCL2 and neutropenia: Besides the reduction of dose when using a Bcl-xL inhibitor, a key study that investigated the neutropenia induced by navitoclax, showed that this was mainly driven by the Bcl-2 inhibition, and not by the Bcl-xL one [35, 37].